服务热线
021-60498804
| Cat. Number | H1753 |
| Chemical Name | H1753 D,L-erythro-PPMP |
| Category | synthetic |
| Mol. Formula | C29H50N2O3•HCl |
| Mol. Weight | 511 |
| Qty 1 |
100mg |
| Appearance | solid |
| Application Notes | 98+% TLC ;HPLC; identity confirmed by MS |
| Synonym | D,L-erythro-1-Phenyl-2-hexadecanoylamino-3-morpholino-1-propanol•HCl |
| Solubility | ethanol,methanol,chloroform,DSMO |
| Storage condition | -20°C |
| References |
D,L-erythro-PPMP is the erythro isomer of the glucosylceramide synthase inhibitor D-threo-PPMP. Whereas D-threo- PPMP is an active inhibitor both D- and L-erythro-PPMP are inactive towards glucosylceramide synthase and can therefore be used for effective comparison studies. Due to PPMP’s ability to inhibit the joining of ceramides with carbohydrates there can be an accumulation of ceramide in the cells and this can lead to apoptosis. It has been suggested that an accumulation of glucosylceramide may cause multidrug-resistance in tumor cells and that PPMP may be useful in reversing or preventing multidrugresistance by blocking the synthesis of glucosylceramides.1 Cells that were incubated with PPMP have been shown to have a 50% decrease in the viral fusion of HIV-1, causing a reduction in the penetration of this virus into these cells.2 PPMP has been used to arrest the growth of the malarial causing parasite Plasmodium falciparum by inhibiting its very specific glucosylceramide synthase, an approach that has great potential for malarial chemotherapy.3 Conduritol B epoxide (CBE), an inhibitor of beta-glucosidase, along with PPMP can be used to create a model of Gaucher disease.4 |
Copyright © 2022 上海惠诚生物科技有限公司
沪ICP备2021037845号-6
